Skip to content

Study · Animal study (in vivo) · mouse · 2020

8 results

Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways.

Ma WH, Li M, Ma HF, Li W, Liu L, Yin Y, Zhou XM, Hou G

Life sciences4 Dec 2019Cited by 55 (Europe PMC)

PMID31809714 (opens in a new tab)DOI10.1016/j.lfs.2019.117139 (opens in a new tab)PepBankPUB-31809714
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with bleomycin-induced pulmonary fibrosis, GHK‑Cu inhibited inflammatory and fibrotic pathological changes.

    In plain wordsIn mice with lung fibrosis, GHK‑Cu reduced inflammatory and scarring changes in the lung.

    Peptide
    GHK-Cu
    Outcome
    DecreaseInflammatory and fibrotic pathological changes
    Study

    mousen: not reported in source

    Bleomycin-induced pulmonary fibrosis
    Outcome group
    Lung injury and fibrosis · Respiratory
    Studied dose
    0.2, 2 and 20 μg/g/day · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    GHK-Cu complex inhibited BLM-induced inflammatory and fibrotic pathological changes
    1 context sentence
    Summary · context
    BLM (3 mg/kg) was administered via tracheal instillation (TI) to induce a pulmonary fibrosis model in C57BL/6j mice 21 days after the challenge of BLM. GHK-Cu was injected intraperitoneally (i.p.) at different dosage of 0.2, 2 and 20 μg/g/day in 0.5 ml PBS on alternate day.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with bleomycin-induced pulmonary fibrosis, GHK‑Cu reduced TNF-α levels in bronchoalveolar lavage fluid.

    In plain wordsIn mice with lung fibrosis, GHK‑Cu lowered the inflammation signal TNF-α in lung fluid.

    Peptide
    GHK-Cu
    Outcome
    DecreaseTNF-α in BALF
    Study

    mousen: not reported in source

    Bleomycin-induced pulmonary fibrosis
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    0.2, 2 and 20 μg/g/day · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    alleviated the inflammatory response in the BALF by reducing the levels of the inflammatory cytokines, TNF-ɑ and IL-6
    1 context sentence
    Summary · context
    BLM (3 mg/kg) was administered via tracheal instillation (TI) to induce a pulmonary fibrosis model in C57BL/6j mice 21 days after the challenge of BLM. GHK-Cu was injected intraperitoneally (i.p.) at different dosage of 0.2, 2 and 20 μg/g/day in 0.5 ml PBS on alternate day.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with bleomycin-induced pulmonary fibrosis, GHK‑Cu reduced IL-6 levels in bronchoalveolar lavage fluid.

    In plain wordsIn mice with lung fibrosis, GHK‑Cu lowered the inflammation signal IL-6 in lung fluid.

    Peptide
    GHK-Cu
    Outcome
    DecreaseIL-6 in BALF
    Study

    mousen: not reported in source

    Bleomycin-induced pulmonary fibrosis
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    0.2, 2 and 20 μg/g/day · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    alleviated the inflammatory response in the BALF by reducing the levels of the inflammatory cytokines, TNF-ɑ and IL-6
    1 context sentence
    Summary · context
    BLM (3 mg/kg) was administered via tracheal instillation (TI) to induce a pulmonary fibrosis model in C57BL/6j mice 21 days after the challenge of BLM. GHK-Cu was injected intraperitoneally (i.p.) at different dosage of 0.2, 2 and 20 μg/g/day in 0.5 ml PBS on alternate day.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice with bleomycin-induced pulmonary fibrosis, GHK‑Cu reduced MPO activity in bronchoalveolar lavage fluid.

    In plain wordsIn mice with lung fibrosis, GHK‑Cu lowered MPO, an inflammation enzyme, in lung fluid.

    Peptide
    GHK-Cu
    Outcome
    DecreaseMPO activity in BALF
    Study

    mousen: not reported in source

    Bleomycin-induced pulmonary fibrosis
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    0.2, 2 and 20 μg/g/day · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    the activity of MPO
    1 context sentence
    Summary · context
    BLM (3 mg/kg) was administered via tracheal instillation (TI) to induce a pulmonary fibrosis model in C57BL/6j mice 21 days after the challenge of BLM. GHK-Cu was injected intraperitoneally (i.p.) at different dosage of 0.2, 2 and 20 μg/g/day in 0.5 ml PBS on alternate day.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice with bleomycin-induced pulmonary fibrosis, GHK‑Cu reduced collagen deposition.

    In plain wordsIn mice with lung fibrosis, GHK‑Cu reduced collagen build-up in the lung.

    Peptide
    GHK-Cu
    Outcome
    DecreaseCollagen deposition
    Study

    mousen: not reported in source

    Bleomycin-induced pulmonary fibrosis
    Outcome group
    Lung injury and fibrosis · Respiratory
    Studied dose
    0.2, 2 and 20 μg/g/day · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    reduced collagen deposition.
    1 context sentence
    Summary · context
    BLM (3 mg/kg) was administered via tracheal instillation (TI) to induce a pulmonary fibrosis model in C57BL/6j mice 21 days after the challenge of BLM. GHK-Cu was injected intraperitoneally (i.p.) at different dosage of 0.2, 2 and 20 μg/g/day in 0.5 ml PBS on alternate day.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In mice with bleomycin-induced pulmonary fibrosis, GHK‑Cu significantly reversed the MMP-9/TIMP-1 imbalance.

    In plain wordsIn mice with lung fibrosis, GHK‑Cu corrected a lung enzyme imbalance.

    Peptide
    GHK-Cu
    Outcome
    DecreaseMMP-9/TIMP-1 imbalance
    Study

    mousen: not reported in source

    Bleomycin-induced pulmonary fibrosis
    Outcome group
    Lung injury and fibrosis · Respiratory
    Studied dose
    0.2, 2 and 20 μg/g/day · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    the GHK-Cu treatment significantly reversed the MMP-9/TIMP-1 imbalance
    1 context sentence
    Summary · context
    BLM (3 mg/kg) was administered via tracheal instillation (TI) to induce a pulmonary fibrosis model in C57BL/6j mice 21 days after the challenge of BLM. GHK-Cu was injected intraperitoneally (i.p.) at different dosage of 0.2, 2 and 20 μg/g/day in 0.5 ml PBS on alternate day.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In mice with bleomycin-induced pulmonary fibrosis, GHK‑Cu partially prevented epithelial-mesenchymal transition.

    In plain wordsIn mice with lung fibrosis, GHK‑Cu partly prevented a cell change linked to scarring.

    Peptide
    GHK-Cu
    Outcome
    DecreaseEpithelial-mesenchymal transition
    Study

    mousen: not reported in source

    Bleomycin-induced pulmonary fibrosis
    Outcome group
    Lung injury and fibrosis · Respiratory
    Studied dose
    0.2, 2 and 20 μg/g/day · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    partially prevented EMT via Nrf2, NF-κB and TGFβ1 pathways, as well as Smad2/3 phosphorylation.
    1 context sentence
    Summary · context
    BLM (3 mg/kg) was administered via tracheal instillation (TI) to induce a pulmonary fibrosis model in C57BL/6j mice 21 days after the challenge of BLM. GHK-Cu was injected intraperitoneally (i.p.) at different dosage of 0.2, 2 and 20 μg/g/day in 0.5 ml PBS on alternate day.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In mice with bleomycin-induced pulmonary fibrosis, GHK‑Cu acted via the Nrf2, NF-κB and TGFβ1 pathways and Smad2/3 phosphorylation; the abstract gives no direction per pathway.

    In plain wordsIn mice with lung fibrosis, GHK‑Cu acted on several cell signalling pathways; the abstract does not give the direction for each.

    Peptide
    GHK-Cu
    Outcome
    Direction not reportedNrf2, NF-κB, TGFβ1 pathways and Smad2/3 phosphorylation
    Study

    mousen: not reported in source

    Bleomycin-induced pulmonary fibrosis
    Outcome group
    Receptor activity and mechanism · Respiratory
    Studied dose
    0.2, 2 and 20 μg/g/day · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    partially prevented EMT via Nrf2, NF-κB and TGFβ1 pathways, as well as Smad2/3 phosphorylation.
    1 context sentence
    Summary · context
    BLM (3 mg/kg) was administered via tracheal instillation (TI) to induce a pulmonary fibrosis model in C57BL/6j mice 21 days after the challenge of BLM. GHK-Cu was injected intraperitoneally (i.p.) at different dosage of 0.2, 2 and 20 μg/g/day in 0.5 ml PBS on alternate day.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.